Blood advances
Increasing ketamine administration in children's hospitals for youth with sickle cell disease.
Ashley Jenkins, Erin Hendry, Alexandra Power-Hays, Marin Valentino, Matthew Hall, Kathryn E Kyler, James W Antoon, Sonya Tang Girdwood, Jennifer Goldman, Armand Morel, Timothy Savage, Lucas Orth, Natasha M Archer
Published: 202510.1182/bloodadvances.2025016826
Abstract
Ketamine is recommended as an opioid-sparing adjunct for sickle cell disease (SCD)-related pain management. Little is known regarding its use in hospitalized youth with SCD. We aimed to describe trends in ketamine administration and examine associati…
Preview only. Read the full abstract at the source